There is also evidence from clinical studies that, although VEGF may not itself directly impact the underlying non-exudative AMD processes, there is a consequential increase in complement activation products in the eye following dosing of intravitreal VEGF-neutralizing agents in patients with choroidal neovascularization. This evidence concerns the gene VEGFA and age-related macular degeneration.